Monosialotetrahexosylganglioside sodium for injection

1. Pharmacology: Monosialotetrahexosylganglioside sodium can promote the functional recovery of central nervous system damage caused by various reasons, has a protective effect on secondary neurodegeneration after injury, has a positive effect on cerebral hemodynamic parameters and brain edema caused by injury, and can reduce nerve cell edema by improving the activity of cell membrane enzymes. Animal experiments show that monosialotetrahexosylganglioside sodium can improve behavioral disorders caused by Parkinson's disease. The mechanism of action is to promote neuroplasticity (including the survival of nerve cells, axon growth and synaptic growth). 2. Toxicology: LD50 is 872mg/kg (i.v.) to 8g/kg (s.v.), depending on the animal species and route of administration. Subacute and chronic toxicity tests, teratogenicity tests, reproductive toxicity tests, perinatal toxicity tests, mutagenicity tests and local toxicity tests conducted on various animals did not show any toxic effects of this product.

Monosialotetrahexosylganglioside sodium is a substance extracted from pig brain that has an effect on nerve cell function damage.

This product is white or off-white freeze-dried block or powder.

Used to treat vascular or traumatic central nervous system damage; Parkinson's disease.

20-40 mg per day, once or divided into several intramuscular injections or slow intravenous drips as prescribed by the doctor. In the acute stage of the disease (especially acute trauma): 100 mg per day, intravenous drip; after 2-3 weeks, change to a maintenance dose of 20-40 mg per day, generally for 6 weeks. For Parkinson's disease, the first dose is 500-1000 mg, intravenous drip; from the second day onwards, 200 mg per day, subcutaneous, intramuscular or intravenous drip, generally for 18 weeks. When used subcutaneously or intramuscularly, dissolve it with water for injection to 10 mg/ml; when used intravenously, dissolve and dilute it with 0.9% sodium chloride injection or 5% glucose injection.

A small number of patients developed a rash reaction after using this product and should be advised to stop using it.

People who have been confirmed to be allergic to this product; hereditary abnormalities of lipid metabolism (ganglioside storage diseases, such as familial Tay-Sachs disease and retinal degeneration).

Precautions for children: So far, no adverse reactions have been reported in children using this product. Precautions for pregnancy and lactation: Experiments conducted on various animals have not shown any adverse reactions to the use of this product during pregnancy and lactation. Precautions for the elderly: So far, no adverse reactions have been reported in elderly patients using this product.

So far, no interaction between this product and other drugs has been found.

Sealed and stored at room temperature.

20mg

24 months

Harbin Medical University Pharmaceutical Co., Ltd.

• Founded in:

  1998-04-08

• Address:

  Bohai Road, Central Area, Haping Road, Harbin Development Zone

• Tax NO.:

  91230199702953105L

• Registered Funds:

  56.9258 million yuan

• Website:

  Log in to view

• Email:

  Log in to view